{"i": ["extended - release oxcarbazepine ( Oxtellar XR \u2122)"], "o": []}
{"i": [], "o": []}
{"i": ["SPN - 804 ( Oxtellar XRTM", "oxcarbazepine ( OXC ),"], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["monthly ( 28 - day ) seizure frequency"]}
{"i": [], "o": ["\u2265 50 % seizure reduction , proportion of patients seizure free", "clinical response and plasma concentration ."]}
{"i": ["placebo"], "o": ["seizure - free rates"]}
{"i": ["SPN - 804", "placebo"], "o": ["percent seizure reduction"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["SPN - 804", "OXC"], "o": ["Adverse event frequency", "peak plasma concentrations"]}
{"i": [], "o": []}
{"i": ["SPN - 804"], "o": []}
{"i": ["OXC"], "o": ["Adverse event occurrence and discontinuations", "tolerability"]}
{"i": ["SPN - 804 ( Oxtellar XRTM", "oxcarbazepine ( OXC ),"], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["monthly ( 28 - day ) seizure frequency"]}
{"i": [], "o": ["\u2265 50 % seizure reduction , proportion of patients seizure free", "clinical response and plasma concentration ."]}
{"i": ["placebo"], "o": ["seizure - free rates"]}
{"i": ["SPN - 804", "placebo"], "o": ["percent seizure reduction"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["SPN - 804", "OXC"], "o": ["Adverse event frequency", "peak plasma concentrations"]}
{"i": [], "o": []}
{"i": ["SPN - 804"], "o": []}
{"i": ["OXC"], "o": ["Adverse event occurrence and discontinuations", "tolerability"]}
{"i": ["carbamazepine ( CBZ )", "Oxcarbazepine ( OXC )"], "o": []}
{"i": ["CBZ 1", "OXC"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["Oxcarbazepine", "licarbazepine"], "o": []}
{"i": ["OXC"], "o": []}
{"i": ["MHD"], "o": []}
{"i": [], "o": []}
{"i": ["placebo - controlled", "OXC - IR", "immediate - release OXC ( OXC - IR )"], "o": []}
{"i": ["OXC - IR"], "o": []}
{"i": [], "o": ["mean trough MHD concentrations", "adverse effects", "dizziness , diplopia , somnolence , vomiting , nausea ."]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["OXC - IR"], "o": []}
{"i": ["OXC - IR"], "o": ["plasma MHD concentrations"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["ER ) OXC"], "o": ["peak plasma MHD concentrations", "tolerability"]}
{"i": ["SPN - 804 ( Oxtellar XRTM"], "o": []}
{"i": ["OXC"], "o": []}
{"i": [], "o": ["MHD concentration"]}
{"i": ["SPN - 804", "OXC - IR"], "o": ["trough MHD concentration", "MHD exposures and peak MHD concentrations"]}
{"i": ["placebo - controlled", "SPN - 804"], "o": ["efficacy , tolerability , and safety"]}
{"i": ["OXC - IR"], "o": []}
{"i": [], "o": []}
{"i": ["placebo - controlled"], "o": []}
{"i": [], "o": ["seizure frequency"]}
{"i": ["SPN - 804", "placebo , SPN - 804"], "o": []}
{"i": [], "o": []}
{"i": ["SPN - 804 or placebo"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["Dosages of concomitant AEDs and vagal nerve stimulator ( VNS ) settings"]}
{"i": [], "o": []}
{"i": ["SPN - 804"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["VNS"], "o": ["seizures"]}
{"i": [], "o": []}
{"i": [], "o": ["seizure counts", "Quality of Life in Epilepsy ( QOLIE - 31 ) questionnaires", "Patient Global Impression of Change ( PGIC )"]}
{"i": [], "o": ["Seizure frequency"]}
{"i": [], "o": ["monthly ( 28 - day ) seizure frequency"]}
{"i": [], "o": ["seizure frequency reduction ), proportion of patients seizure free , and changes in PGIC and QOLIE - 31 scores .", "responder rate ( proportion"]}
{"i": [], "o": []}
{"i": [], "o": ["treatment - emergent adverse events coded using the Medical Dictionary for Regulatory Affairs ( MedDRA ), neurologic / physical examinations , clinical laboratory values , vital signs , and ECG tracings"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["OXC and MHD concentrations"]}
{"i": [], "o": ["apparent oral clearance ( CL / F ), maximum ( Cmax ), and minimum / trough ( Cmin ) concentrations for OXC"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["OXC - IR", "placebo"], "o": []}
{"i": ["SPN - 804", "placebo"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["SPN - 804"], "o": []}
{"i": [], "o": ["seizure frequency"]}
{"i": ["placebo", "placebo ."], "o": ["percent seizure frequency change"]}
{"i": ["placebo ."], "o": []}
{"i": ["SPN - 804"], "o": []}
{"i": ["placebo"], "o": []}
{"i": ["placebo"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["SPN - 804", "placebo"], "o": []}
{"i": [], "o": ["seizure - free rates"]}
{"i": [], "o": []}
{"i": [], "o": ["seizure - free rates ."]}
{"i": [], "o": ["PGIC score changes"]}
{"i": [], "o": ["QOLIE - 31 subscale scores , total score , and health status score"]}
{"i": [], "o": ["seizure frequency reduction"]}
{"i": ["SPN - 804", "placebo"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["SPN - 804"], "o": []}
{"i": ["placebo"], "o": []}
{"i": [], "o": ["adverse events"]}
{"i": ["placebo"], "o": ["pill counts"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["median monthly seizure frequency", "number of years since"]}
{"i": ["Oxtellar XR", "Placebo"], "o": []}
{"i": ["SPN - 804"], "o": []}
{"i": ["placebo"], "o": ["seizure frequency change"]}
{"i": [], "o": []}
{"i": ["SPN - 804", "placebo"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["placebo"], "o": []}
{"i": ["SPN - 804", "placebo"], "o": ["responder rates"]}
{"i": ["placebo"], "o": ["seizure free", "seizure freedom"]}
{"i": ["SPN - 804", "placebo"], "o": []}
{"i": ["SPN - 804", "placebo"], "o": ["seizure reduction"]}
{"i": [], "o": []}
{"i": ["SPN - 804", "placebo"], "o": []}
{"i": ["placebo"], "o": []}
{"i": ["SPN - 804", "placebo"], "o": []}
{"i": ["SPN - 804", "placebo"], "o": ["PGIC score changes"]}
{"i": ["placebo"], "o": ["Mean total QOLIE - 31 and subscale scores"]}
{"i": ["placebo"], "o": ["QOLIE - 31 score", "QOLIE - 31 subscales of Cognitive Functioning", "Medication Effects"]}
{"i": ["placebo"], "o": ["adverse events"]}
{"i": ["SPN - 804", "placebo"], "o": ["specific adverse events"]}
{"i": ["placebo"], "o": ["to the nervous system"]}
{"i": [], "o": ["dizziness , nausea , somnolence , vomiting , headache , and diplopia \u2013"]}
{"i": ["placebo"], "o": ["Treatment - limiting adverse event rates"]}
{"i": [], "o": ["adverse events"]}
{"i": ["Oxtellar XR", "Placebo"], "o": []}
{"i": ["SPN - 804", "placebo"], "o": ["Serious adverse events"]}
{"i": ["placebo"], "o": []}
{"i": ["placebo"], "o": []}
{"i": ["SPN - 804"], "o": ["headache .", "dizziness", "hyponatremia", "generalized rash", "dizziness , diplopia , nausea , vomiting , abdominal pain", "vomiting"]}
{"i": ["SPN - 804"], "o": []}
{"i": [], "o": ["laboratory , vital sign , or ECG abnormality"]}
{"i": ["placebo"], "o": ["normal to lower serum sodium levels"]}
{"i": ["SPN - 804"], "o": ["Serum sodium levels"]}
{"i": [], "o": ["abnormal sodium value", "symptomatic hyponatremia"]}
{"i": ["SPN - 804"], "o": ["mean ( SD ) Cmax of MHD", "Cmin concentrations", "plasma MHD concentrations"]}
{"i": ["carbamazepine , phenytoin , phenobarbital", "valproate"], "o": ["Clearance"]}
{"i": ["SPN - 804"], "o": ["trough ( Cmin ) MHD concentrations ."]}
{"i": [], "o": []}
{"i": [], "o": ["overall median Cmin"]}
{"i": ["placebo"], "o": ["Median percent seizure frequency reduction"]}
{"i": ["SPN - 804"], "o": ["Cmin"]}
{"i": ["SPN - 804 ( Oxtellar XR )"], "o": []}
{"i": ["SPN - 804", "placebo"], "o": []}
{"i": ["SPN - 804"], "o": ["median percent seizure reduction"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["placebo"], "o": []}
{"i": ["SPN - 804", "placebo"], "o": []}
{"i": ["placebo"], "o": []}
{"i": ["SPN - 804", "placebo"], "o": ["median percent seizure reduction"]}
{"i": ["SPN - 804"], "o": ["trough MHD concentrations"]}
{"i": ["placebo"], "o": []}
{"i": ["placebo"], "o": []}
{"i": [], "o": []}
{"i": ["perampanel", "placebo"], "o": []}
{"i": ["placebo"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["placebo", "lacosamide"], "o": []}
{"i": ["placebo"], "o": ["monthly seizure frequency"]}
{"i": ["placebo"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["adherence rates"]}
{"i": [], "o": ["emergency department / inpatient visits"]}
{"i": [], "o": []}
{"i": ["ER AED"], "o": []}
{"i": ["b . i . d .", "lamotrigine"], "o": []}
{"i": ["CBZ - IR"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["CBZ - ER", "CBZ - IR"], "o": ["therapeutic success", "patient retention"]}
{"i": ["CBZ - ER vs CBZ - IR"], "o": []}
{"i": [], "o": ["plasma concentration"]}
{"i": ["SPN - 804"], "o": ["plasma MHD exposure"]}
{"i": ["OXC - IR ( Trileptal )", "SPN - 804"], "o": []}
{"i": ["SPN - 804"], "o": []}
{"i": [], "o": ["dizziness", "Dizziness"]}
{"i": [], "o": []}
{"i": ["SPN - 804"], "o": []}
{"i": ["OXC - IR"], "o": []}
{"i": [], "o": ["rate of discontinuations due to adverse events"]}
{"i": ["OXC - IR"], "o": []}
{"i": ["SPN - 804"], "o": ["ataxia", "diplopia", "nausea", "dizziness", "somnolence", "vomiting"]}
{"i": [], "o": ["OXC - IR"]}
{"i": [], "o": []}
{"i": ["OXC - IR"], "o": []}
{"i": ["SPN - 804", "OXC - IR"], "o": ["MHD exposure", "treatment - limiting adverse events ."]}
{"i": [], "o": []}
{"i": ["OXC - IR"], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["seizure - free rates"]}
{"i": ["SPN - 804"], "o": ["seizure - free rates", "ITT seizure - free rate"]}
{"i": ["SPN - 804"], "o": ["tolerability and effectiveness"]}
{"i": ["SPN - 804 ( Oxtellar XR )"], "o": ["plasma MHD concentrations"]}
{"i": ["SPN - 804", "OXC - IR"], "o": []}
{"i": [], "o": []}
{"i": ["SPN - 804"], "o": ["plasma MHD concentrations"]}
